Mag Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.65 M
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 13.27%
- Profit Growth 67.39%
- Ebitda -16.20%
- Net Worth 15.66%
- Total Assets 16.01%
About Mag Pharma
Mag Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 June 2008 and has a history of 16 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.65 M, as per Ministry of Corporate Affairs (MCA) records.
Farhana Usmani, Mohd Khan, Danish Khan, and Two other members serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51397DL2008PTC179172
-
Company No.
179172
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jun 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mag Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Danish Khan
|
Director | 30-Sep-2021 | Current |
|
Farhana Usmani
|
Director | 06-Jun-2008 | Current |
|
Mohd Khan
|
Director | 30-Sep-2021 | Current |
|
Hussain
|
Director | 29-Apr-2022 | Current |
|
Kausar Parveen
|
Director | 01-Jul-2022 | Current |
Financial Performance of Mag Pharma.
Mag Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.27% increase. The company also saw a substantial improvement in profitability, with a 67.39% increase in profit. The company's net worth Soared by an impressive increase of 15.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mag Pharma?
In 2022, Mag Pharma had a promoter holding of 23.08% and a public holding of 76.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rex Remedies Distributors Private LimitedHussain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mag Pharma?
Unlock and access historical data on people associated with Mag Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mag Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mag Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
